Roche Forges Ahead With Taspoglutide Despite Other GLP-1 Cancer Signal
This article was originally published in Pharmaceutical Approvals Monthly
Roche is forging ahead with its glucagon-like peptide-1 analog taspoglutide despite reports of adenomas (benign tumors) in animal studies and the stumbling block Novo Nordisk hit with its competing type 2 diabetes product Victoza (liraglutide) due to a thyroid cancer signal in animals
You may also be interested in...
Liraglutide’s cardiovascular safety profile gets support from a majority of an FDA advisory committee, but a preclinical thyroid cancer risk results in a tied vote on the approvability of Novo Nordisk’s type 2 diabetes drug.
FDA's flexibility in applying its new guidance for cardiovascular safety of diabetes drugs will be tested in coming months as it reviews a handful of pending NDAs and enters into discussions about other drugs in late stages of development
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.